BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15016320)

  • 1. Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray.
    Nagahata T; Onda M; Emi M; Nagai H; Tsumagari K; Fujimoto T; Hirano A; Sato T; Nishikawa K; Akiyama F; Sakamoto G; Kasumi F; Miki Y; Tanaka T; Tsunoda T
    Cancer Sci; 2004 Mar; 95(3):218-25. PubMed ID: 15016320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative prognosis of node-negative breast cancers predicted by gene-expression profiling on a cDNA microarray of 25,344 genes.
    Tsumagari K; Chijiiwa K; Nagai H; Makita M; Kasumi F; Akiyama F; Sakamoto G; Miki Y
    Breast Cancer; 2005; 12(3):166-77. PubMed ID: 16110286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene expression patterns as marker for 5-year postoperative prognosis of primary breast cancers.
    Onda M; Emi M; Nagai H; Nagahata T; Tsumagari K; Fujimoto T; Akiyama F; Sakamoto G; Makita M; Kasumi F; Miki Y; Tanaka T; Tsunoda T; Nakamura Y
    J Cancer Res Clin Oncol; 2004 Sep; 130(9):537-45. PubMed ID: 15235906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF/MEK Pathway is Associated With Breast Cancer in ER-dependent Mode and Improves ER Status-based Cancer Recurrence Prediction.
    Liu D; Zhou K
    Clin Breast Cancer; 2020 Feb; 20(1):41-50.e8. PubMed ID: 31547956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of gene expression profiles predicting progression in breast cancer patients treated with tamoxifen.
    Kok M; Linn SC; Van Laar RK; Jansen MP; van den Berg TM; Delahaye LJ; Glas AM; Peterse JL; Hauptmann M; Foekens JA; Klijn JG; Wessels LF; Van't Veer LJ; Berns EM
    Breast Cancer Res Treat; 2009 Jan; 113(2):275-83. PubMed ID: 18311582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of two genes selected by iAFLP: a new prognostic factor of estrogen receptor-positive breast cancer.
    Aritake N; Tamaki Y; Masuda N; Nakano Y; Monden T; Noguchi S; Monden M
    Oncol Rep; 2004 Aug; 12(2):381-7. PubMed ID: 15254706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer.
    Iwamoto T; Bianchini G; Booser D; Qi Y; Coutant C; Shiang CY; Santarpia L; Matsuoka J; Hortobagyi GN; Symmans WF; Holmes FA; O'Shaughnessy J; Hellerstedt B; Pippen J; Andre F; Simon R; Pusztai L
    J Natl Cancer Inst; 2011 Feb; 103(3):264-72. PubMed ID: 21191116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 18F-FDG PET of locally invasive breast cancer and association of estrogen receptor status with standardized uptake value: microarray and immunohistochemical analysis.
    Osborne JR; Port E; Gonen M; Doane A; Yeung H; Gerald W; Cook JB; Larson S
    J Nucl Med; 2010 Apr; 51(4):543-50. PubMed ID: 20237034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and Therapeutic Significance of Adhesion-regulating Molecule 1 in Estrogen Receptor-positive Breast Cancer.
    Wu W; Zhong J; Chen J; Niu P; Ding Y; Han S; Xu J; Dai L
    Clin Breast Cancer; 2020 Apr; 20(2):131-144.e3. PubMed ID: 31669266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.
    Smith DD; Saetrom P; Snøve O; Lundberg C; Rivas GE; Glackin C; Larson GP
    BMC Bioinformatics; 2008 Jan; 9():63. PubMed ID: 18226260
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression pattern of stromal cell-derived factor-1 chemokine in invasive breast cancer is correlated with estrogen receptor status and patient prognosis.
    Kobayashi T; Tsuda H; Moriya T; Yamasaki T; Kikuchi R; Ueda S; Omata J; Yamamoto J; Matsubara O
    Breast Cancer Res Treat; 2010 Oct; 123(3):733-45. PubMed ID: 20020198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiles obtained from fine-needle aspirations of breast cancer reliably identify routine prognostic markers and reveal large-scale molecular differences between estrogen-negative and estrogen-positive tumors.
    Pusztai L; Ayers M; Stec J; Clark E; Hess K; Stivers D; Damokosh A; Sneige N; Buchholz TA; Esteva FJ; Arun B; Cristofanilli M; Booser D; Rosales M; Valero V; Adams C; Hortobagyi GN; Symmans WF
    Clin Cancer Res; 2003 Jul; 9(7):2406-15. PubMed ID: 12855612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A candidate molecular signature associated with tamoxifen failure in primary breast cancer.
    Vendrell JA; Robertson KE; Ravel P; Bray SE; Bajard A; Purdie CA; Nguyen C; Hadad SM; Bieche I; Chabaud S; Bachelot T; Thompson AM; Cohen PA
    Breast Cancer Res; 2008; 10(5):R88. PubMed ID: 18928543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.
    Bianchini G; Qi Y; Alvarez RH; Iwamoto T; Coutant C; Ibrahim NK; Valero V; Cristofanilli M; Green MC; Radvanyi L; Hatzis C; Hortobagyi GN; Andre F; Gianni L; Symmans WF; Pusztai L
    J Clin Oncol; 2010 Oct; 28(28):4316-23. PubMed ID: 20805453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.
    Alles MC; Gardiner-Garden M; Nott DJ; Wang Y; Foekens JA; Sutherland RL; Musgrove EA; Ormandy CJ
    PLoS One; 2009; 4(3):e4710. PubMed ID: 19270750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-1290 and its potential targets are associated with characteristics of estrogen receptor α-positive breast cancer.
    Endo Y; Toyama T; Takahashi S; Yoshimoto N; Iwasa M; Asano T; Fujii Y; Yamashita H
    Endocr Relat Cancer; 2013 Feb; 20(1):91-102. PubMed ID: 23183268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of KAI1/CD82 in distant metastases from estrogen receptor-negative breast cancer.
    Christgen M; Christgen H; Heil C; Krech T; Länger F; Kreipe H; Lehmann U
    Cancer Sci; 2009 Sep; 100(9):1767-71. PubMed ID: 19549254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.
    Yau C; Fedele V; Roydasgupta R; Fridlyand J; Hubbard A; Gray JW; Chew K; Dairkee SH; Moore DH; Schittulli F; Tommasi S; Paradiso A; Albertson DG; Benz CC
    Breast Cancer Res; 2007; 9(5):R59. PubMed ID: 17850661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
    Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
    Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.